Abstract
IL-10,along with interleukin(IL)-6,are considered two of the most important cytokines that regulate the proliferation and cellular characteristics of myeloma cells. It remains unclear from the clinical data how levels of IL-10 in serum at various stages of myeloma are related to clinical manifestations of this disease. Several studies have reported that IL-10 affects myeloma cells by stimulating secondary signals for cell proliferation through oncostatin M (OSM)and IL-11. In experiments using human myeloma cell lines that were established in our laboratory,IL-10 seemed to be expressed in half of myelomas simultaneously with OSM,and was correlated with c-maf,a transcription factor that has been known to be overexpressed in myelomas with t (14;16)(q32;q23). In addition,IL-10 abolishes all trans-retinoic acid (ATRA)-induced growth inhibition of myeloma cells. The expression and production of IL-10 in myeloma patients may be important for sub-categorization and to establish case-oriented therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Clinical and Experimental Hematopathology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.